Tirzepatide Trial Demonstrates Substantial Weight Loss

JAMA. 2022 Jul 26;328(4):322. doi: 10.1001/jama.2022.11895.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Anti-Obesity Agents* / pharmacology
  • Anti-Obesity Agents* / therapeutic use
  • Diabetes Mellitus, Type 2 / drug therapy
  • Gastric Inhibitory Polypeptide
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Incretins* / pharmacology
  • Incretins* / therapeutic use
  • Tirzepatide
  • Weight Loss* / drug effects

Substances

  • Anti-Obesity Agents
  • Hypoglycemic Agents
  • Incretins
  • Gastric Inhibitory Polypeptide
  • Tirzepatide